These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 9250826)
1. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype. Pope B; Brown R; Luo XF; Gibson J; Joshua D Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826 [TBL] [Abstract][Full Text] [Related]
2. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Brown RD; Pope B; Luo XF; Gibson J; Joshua D Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921 [TBL] [Abstract][Full Text] [Related]
3. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906 [TBL] [Abstract][Full Text] [Related]
4. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531 [TBL] [Abstract][Full Text] [Related]
5. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Pope B; Brown RD; Gibson J; Petersen A; Wiley J; Joshua DE Leuk Lymphoma; 1997 Sep; 27(1-2):83-91. PubMed ID: 9373199 [TBL] [Abstract][Full Text] [Related]
6. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855 [TBL] [Abstract][Full Text] [Related]
7. Elevated c-myc messenger RNA in multiple myeloma cell lines. Fourney R; Palmer M; Ng A; Dietrich K; Belch A; Paterson M; Brox L Dis Markers; 1990; 8(3):117-24. PubMed ID: 1980237 [TBL] [Abstract][Full Text] [Related]
8. Oncogenes in multiple myeloma: point mutation of N-ras. Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133 [TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957 [TBL] [Abstract][Full Text] [Related]
10. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions. Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596 [No Abstract] [Full Text] [Related]
11. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011 [TBL] [Abstract][Full Text] [Related]
12. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Greil R; Fasching B; Loidl P; Huber H Blood; 1991 Jul; 78(1):180-91. PubMed ID: 2070052 [TBL] [Abstract][Full Text] [Related]
13. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094 [No Abstract] [Full Text] [Related]
14. Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Palumbo AP; Pileri A; Dianzani U; Massaia M; Boccadoro M; Calabretta B Cancer Res; 1989 Sep; 49(17):4701-4. PubMed ID: 2667753 [TBL] [Abstract][Full Text] [Related]
15. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763 [TBL] [Abstract][Full Text] [Related]
16. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. Chim CS; Liang R; Leung MH; Kwong YL J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358 [TBL] [Abstract][Full Text] [Related]
17. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Davies FE; Dring AM; Li C; Rawstron AC; Shammas MA; O'Connor SM; Fenton JA; Hideshima T; Chauhan D; Tai IT; Robinson E; Auclair D; Rees K; Gonzalez D; Ashcroft AJ; Dasgupta R; Mitsiades C; Mitsiades N; Chen LB; Wong WH; Munshi NC; Morgan GJ; Anderson KC Blood; 2003 Dec; 102(13):4504-11. PubMed ID: 12947006 [TBL] [Abstract][Full Text] [Related]
18. Deletion of the retinoblastoma gene in multiple myeloma. Dao DD; Sawyer JR; Epstein J; Hoover RG; Barlogie B; Tricot G Leukemia; 1994 Aug; 8(8):1280-4. PubMed ID: 8057662 [TBL] [Abstract][Full Text] [Related]